期刊
ARCHIVES OF OPHTHALMOLOGY
卷 128, 期 3, 页码 349-358出版社
AMER MEDICAL ASSOC
DOI: 10.1001/archophthalmol.2010.18
关键词
-
资金
- National Institutes of Health [R24 EY017404, R01 EY13435]
- Research to Prevent Blindness Inc
- Macula Vision Research Foundation
- Wallach Foundation
- Elyachar Foundation
- Kaplen Foundation
- Wigdeon Point Charitable Foundation
- Ruth and Milton Steinbach Foundation
- Alcon Research Institute
Age-related macular degeneration (AMD) is one of the most well-characterized late-onset, complex trait diseases. Remarkable advances in our understanding of the genetic and biological foundations of this disease were derived from a recent convergence of scientific and clinical data. Importantly, the more recent identification of AMD-associated variations in a number of complement pathway genes has provided strong support for earlier, paradigm-shifting studies that suggested that aberrant function of the complement system plays a key role in disease etiology. Collectively, this wealth of information has provided an impetus for the development of powerful tools to accurately diagnose disease risk and progression and complement-based therapeutics that will ultimately delay or prevent AMD. Indeed, we are poised to witness a new era of a personalized approach toward the assessment, management, and treatment of this debilitating, chronic disease. Arch Ophthalmol. 2010;128(3):349-358
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据